NEW YORK (GenomeWeb) – Roche announced on Monday that its Cobas methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) nucleic acid test has received CE-IVD marking for use on the firm's Liat PCR point-of-care platform.
The test, which is now available in the EU, simultaneously detects MRSA and SA in less than 30 minutes in a single sample, Roche said. It is designed to support rapid screening and surveillance of these healthcare-acquired infections in emergency rooms, intensive care units, and labs.
"The speed, performance, and simplicity of the Cobas MRSA/SA test provide healthcare professionals with a better chance to reduce disease proliferation, as well as the opportunity to make timely patient management decisions," Roche Diagnostics CEO Roland Diggelmann said in a statement.
The MRSA/SA test is the fifth Cobas assay for use on the Liat PCR system. Earlier this year, Roche announced that the system had received CE marking along with an assay for Clostridium difficile. Cobas Influenza A/B, Strep A, and Influenza A/B & RSV tests were CE marked in 2015 and 2016.